By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    physical health
    5 Ways Playing Games Can Improve Neural and Physical Health
    September 9, 2022
    Reasons For Hair Loss and Its Treatment
    Reasons For Hair Loss and Its Treatment
    February 16, 2022
    healthcare organization
    5 Actionable Strategies For Healthcare Organizations
    August 15, 2022
    Latest News
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    The Latest Numbers on Exchange Enrollment
    January 20, 2014
    conversational AI in healthcare
    How Conversational AI is Making Healthcare More Patient-Centric
    July 24, 2024
    create tracking metrics HIS
    Create Tracking Metrics for ICD-10 Preparation
    February 18, 2014
    Latest News
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
    Top HIPAA-Compliant Messaging Apps for Healthcare Teams
    June 25, 2025
    When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
    June 20, 2025
    Preventing Contamination In Healthcare Facilities Starts With Hygiene
    June 15, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Lawyers and Medical Decision-Making
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Lawyers and Medical Decision-Making
Business

Lawyers and Medical Decision-Making

gooznews
gooznews
Share
4 Min Read
SHARE

We’ve heard a lot over the years about the inappropriate role of lawyers in the medical system. The complaints usually center  on trial lawyers who sue physicians for malpractice and drug companies for failure to warn consumers about unsafe drugs and devices. We’ve heard much less about lawyers who work for drug companies and try to game the regulatory system.

We’ve heard a lot over the years about the inappropriate role of lawyers in the medical system. The complaints usually center  on trial lawyers who sue physicians for malpractice and drug companies for failure to warn consumers about unsafe drugs and devices. We’ve heard much less about lawyers who work for drug companies and try to game the regulatory system.

This latter problem was in full display this afternoon at the FDA hearing on Roche/Genentech’s appeal of the FDA’s decision to remove breast cancer from Avastin’s label.  Paul Schmidt, a Covington & Burling attorney representing Genentech, repeatedly tried to pin down FDA oncology drugs chief Richard Pazdur and his colleagues as to whether they had ever specified that replicating the progression free survival benefit seen in the first trial that led to accelerated approval would satisfy the FDA and therefore lead to permanent approval.

Pazdur repeatedly replied that progression free survival was a surrogate marker of benefit and had to be accompanied by some other benefit, such as improved quality of life. Of course, a trial showing extended survival would be the best. But given the adverse events profile of Avastin — increased cardiovascular deaths; GI perforations; an increase in hypertension in a quarter of patients — any increase in time before a tumor began progressing as the sole benefit would have to be substantial before a drug would be approved based on that surrogate marker alone.

More Read

Listen to Your Patient and They Will Tell You the Problem: A True Story
Supreme Court: Can State Governments Dictate How Publicly Available Information Can Be Used?
Annual Healthcare Costs For Family of 4 Now At $22,030
Wi-Fi Alliance® and Continua® Health Alliance Collaborate on Personal Connected Health
pharmaphorum: Patient Opinion Leaders Are the New Healthcare Influencers

“The approval process is not about a median progression free survival,” Pazur said. “It’s about a risk benefit analysis. The magnitude of a progression free survival change has to be viewed in the context of the safety profile of the drug, the disease setting, the existing therapies, and patient performance status. For me to give you an exact progression free survival would be impossible to do.”

Schmidt pressed ahead: “Did CDER say to Genentech that .8 months progression free survival (the amount seen in one of the follow-up trials) wouldn’t be enough to support approval?”

“I don’t believe we ever said that,” Pazdur said. “All we’re asking for here is one trial that shows clinical benefit.”

There has only been one new piece of clinical evidence introduced at this hearing. A phase II trial published in Lancet Oncology in April, where Avastin was added to several chemotherapy regimens, showed it slightly increased the time before the cancer resumes progressing by a few months — again! — and had no impact on the long-term mortality rate for women struck by a recurrence of this devastating disease.

So, there have been five follow-up trials, and not one has replicated the initial evidence that led to accelerated approval. Tomorrow, Genentech and its lawyers get to present their side of the story. If the company attempts to present new evidence, it will violate the ground rules set by the FDA for the hearing (not to mention normal legal procedures). Why do I think the real purpose of this hearing is to lay the groundwork for a lawsuit against the FDA?

TAGGED:AvastinFDAGenentechhealthcare businesshealthcare law
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

car accident lawsuit
Let Your Lawyer Handle the Work Before You Pay Medical Costs
Policy & Law
July 6, 2025
women dental care
What Is a Smile Makeover and How Much Does It Cost?
Dental health
June 30, 2025
HIPAA-Compliant Messaging Apps
Top HIPAA-Compliant Messaging Apps for Healthcare Teams
Global Healthcare Policy & Law Technology
June 25, 2025
recovering from injury
Rebuilding After Injury: Path to Physical and Emotional Recovery
News
June 22, 2025

You Might also Like

AdvaMed 2011 Featuring Over 70 Company Presentations

September 9, 2011

Collaborating for Mobile Health Innovation

December 9, 2012

What It Takes to Write a Great Case Study

July 1, 2015
BusinessNews

Doctors 2.0 – Second Post

June 9, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?